Guifang Yu
Overview
Explore the profile of Guifang Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu J, Liang J, Xiao G, He Z, Yu G, Zhang L, et al.
Cancer Inform
. 2024 Dec;
23:11769351241307492.
PMID: 39687501
Objectives: Lung adenocarcinoma (LUAD), a predominant form of lung cancer, is characterized by a high rate of metastasis and recurrence, leading to a poor prognosis for LUAD patients. This study...
2.
Wang Y, Yu G, Chen X
Cancer Drug Resist
. 2024 Dec;
7:47.
PMID: 39624080
Ferroptosis is an iron-dependent cell death characterized by increased intracellular lipid peroxidation. Inducing ferroptosis has shown significant potential in eliminating various malignancies. However, the effectiveness of ferroptosis-based treatments is hampered...
3.
Ye W, Hou K, Tao N, Li W, Tan Z, Huang Q, et al.
Oncol Lett
. 2024 Jun;
28(2):369.
PMID: 38933807
Introducing the exploration of stimulated CD4 cells adenosine triphosphate (sATP) levels for immune monitoring post non-small cell lung cancer (NSCLC) chemotherapy, the present study aimed to investigate its efficacy in...
4.
Hou K, Ye W, Huang Q, Li W, Tan Z, Tao N, et al.
BMC Immunol
. 2024 Jan;
25(1):3.
PMID: 38184521
Objective: Lung cancer with the highest incidence and mortality in the world. Immune checkpoint inhibitors (ICIs), can bring long-term survival benefits to patients, but also can bring immune-related adverse events...
5.
Yu Z, Qin L, Yu G
Cancer Treat Res Commun
. 2023 Sep;
37:100758.
PMID: 37776694
Lung cancer has the highest mortality rate of all cancers worldwide. Although immune checkpoint inhibitor (ICI)-based therapy can improve the survival of patients with lung cancer, its efficacy is affected...
6.
Ma C, Huang W, Wang H, Yao W, Liang M, Yu G, et al.
Mol Med
. 2022 Dec;
28(1):151.
PMID: 36503493
Background: Endometriosis (EMS) is a "tumour-like" gynaecological disease with distant metastasis, and studies have shown that EMS can induce distant metastasis through vascular vessels, but the driving factors and their...
7.
Meng Y, Yang L, Wei X, Luo H, Hu Y, Tao X, et al.
Biochem Biophys Res Commun
. 2021 Jul;
567:222-229.
PMID: 34217974
Cyclin D1 (CCND1) has been identified as a metastatic promoter in various tumors including lung adenocarcinoma (LUAD), a subtype of non small cell lung cancer (NSCLC). The previous observation revealed...
8.
Liu J, Wen Y, Liu Z, Liu S, Xu P, Xu Y, et al.
Mol Ther Nucleic Acids
. 2021 Jan;
23:324-335.
PMID: 33425490
VPS33B is reported to be a tumor suppressor in hepatocellular carcinoma, nasopharyngeal carcinoma, colon cancer, and lung adenocarcinoma. Here, we observed that reduced VPS33B protein level was an unfavorable factor...
9.
Li Y, Lv Y, Cheng C, Huang Y, Yang L, He J, et al.
Cell Death Dis
. 2020 Jul;
11(7):509.
PMID: 32641685
SPEN family transcriptional repressor (SPEN), also known as the SMART/HDAC1-associated repressor protein (SHARP), has been reported to modulate the malignant phenotypes of breast cancer, colon cancer, and ovarian cancer. However,...
10.
Lin X, Zuo S, Luo R, Li Y, Yu G, Zou Y, et al.
Theranostics
. 2019 Nov;
9(25):7583-7598.
PMID: 31695788
Cancer stem cells (CSCs) are the key factor in determining cancer recurrence, metastasis, chemoresistance and patient prognosis in hepatocellular carcinoma (HCC). The role of miR-5188 in cancer stemness has never...